Literature DB >> 32068517

Comparison of lateral surgical margins of up to two centimeters with margins of three centimeters for achieving tumor-free histologic margins following excision of grade I or II cutaneous mast cell tumors in dogs.

Margaret L Chu, Galina M Hayes, Joshua G Henry, Michelle L Oblak.   

Abstract

OBJECTIVE: To determine whether conservative lateral surgical margins (equal to tumor diameter for tumors < 2 cm in diameter or 2 cm for larger tumors) were noninferior to wide (3-cm) lateral surgical margins for achieving tumor-free histologic margins following excision of grade I and II cutaneous mast cell tumors (MCTs) in dogs. ANIMALS: 83 grade I and II MCTs excised with a deep surgical fascial margin and requisite lateral surgical margins from 68 dogs from 2007 to 2017. Tumors representing scar revision or local recurrence were excluded. PROCEDURES: A pathology department database was searched to identify qualifying MCTs, and medical records were cross-referenced to obtain data regarding patients and tumors. Outcome (complete vs incomplete excision as histologically determined) was compared between conservative- and wide-margin groups. A noninferiority margin of ≥ 0.9 was used for the risk ratio (probability of complete excision for the conservative- vs wide-margin group), implying that noninferiority would be established if the data indicated that the true risk of complete excision with the conservative-margin approach was at worst 90% of that for the wide-margin approach.
RESULTS: The proportion of excised MCTs with tumor-free histologic margins was similar between the conservative- (43/46 [93%]) and wide- (34/37 [92%]) margin groups. There were no differences in tumor diameter or location between treatment groups. The risk ratio (1.02; 95% confidence interval, 0.89 to 1.19) met the criterion for noninferiority. CONCLUSIONS AND CLINICAL RELEVANCE: The conservative-margin approach appeared to be noninferior to the wide-margin approach for achieving tumor-free histologic margins in the dogs of this study, and its use could potentially reduce the risk of postoperative complications. (J Am Vet Med Assoc 2020;256:567-572.

Entities:  

Mesh:

Year:  2020        PMID: 32068517     DOI: 10.2460/javma.256.5.567

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  5 in total

1.  Long-term postsurgical outcomes of mast cell tumors resected with a margin proportional to the tumor diameter in 23 dogs.

Authors:  Teruo Itoh; Atsuko Kojimoto; Kazuyuki Uchida; James Chambers; Hiroki Shii
Journal:  J Vet Med Sci       Date:  2020-12-21       Impact factor: 1.267

2.  Tigilanol Tiglate-Mediated Margins: A Comparison With Surgical Margins in Successful Treatment of Canine Mast Cell Tumours.

Authors:  Thomas De Ridder; Paul Reddell; Pamela Jones; Graham Brown; Justine Campbell
Journal:  Front Vet Sci       Date:  2021-12-15

Review 3.  Diagnosis, Prognosis and Treatment of Canine Cutaneous and Subcutaneous Mast Cell Tumors.

Authors:  Andrigo Barboza de Nardi; Rodrigo Dos Santos Horta; Carlos Eduardo Fonseca-Alves; Felipe Noleto de Paiva; Laís Calazans Menescal Linhares; Bruna Fernanda Firmo; Felipe Augusto Ruiz Sueiro; Krishna Duro de Oliveira; Silvia Vanessa Lourenço; Ricardo De Francisco Strefezzi; Carlos Henrique Maciel Brunner; Marcelo Monte Mor Rangel; Paulo Cesar Jark; Jorge Luiz Costa Castro; Rodrigo Ubukata; Karen Batschinski; Renata Afonso Sobral; Natália Oyafuso da Cruz; Adriana Tomoko Nishiya; Simone Crestoni Fernandes; Simone Carvalho Dos Santos Cunha; Daniel Guimarães Gerardi; Guilherme Sellera Godoy Challoub; Luiz Roberto Biondi; Renee Laufer-Amorim; Paulo Ricardo de Oliveira Paes; Gleidice Eunice Lavalle; Rafael Ricardo Huppes; Fabrizio Grandi; Carmen Helena de Carvalho Vasconcellos; Denner Santos Dos Anjos; Ângela Cristina Malheiros Luzo; Julia Maria Matera; Miluse Vozdova; Maria Lucia Zaidan Dagli
Journal:  Cells       Date:  2022-02-10       Impact factor: 6.600

4.  Evaluation of Tumor Grade and Proliferation Indices before and after Short-Course Anti-Inflammatory Prednisone Therapy in Canine Cutaneous Mast Cell Tumors: A Pilot Study.

Authors:  Shawna Klahn; Nikolaos Dervisis; Kevin Lahmers; Marian Benitez
Journal:  Vet Sci       Date:  2022-06-07

5.  Recurrence-free interval 12 months after local treatment of mast cell tumors in dogs using intratumoral injection of tigilanol tiglate.

Authors:  Pamela D Jones; Justine E Campbell; Graham Brown; Chad M Johannes; Paul Reddell
Journal:  J Vet Intern Med       Date:  2020-12-22       Impact factor: 3.175

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.